New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Estimated proportion of cancer deaths not addressed by current cancer screening efforts in the United States.
Estimated proportion of cancer deaths not addressed by current cancer screening efforts in the United States. Cancer biomarkers : section A of Disease markers Ofman, J. J., Dahut, W., Jemal, A., Chang, E. T., Clarke, C. A., Hubbell, E., Kansal, A. R., Kurian, A. W., Colditz, G. A., Patel, A. V. 2025; 42 (1): 18758592241308754Abstract
BackgroundIt is unclear what proportion of the population cancer burden is covered by current implementation of USPSTF A/B screening recommendations.ObjectiveWe estimated the proportion of all US cancer deaths caused by cancer types not covered by screening recommendations or cancer types covered but unaddressed by current implementation.MethodsWe used 2018-2019 National Center for Health Statistics mortality data, Surveillance, Epidemiology, and End Results registries incidence-based mortality data, and published estimates of screening eligibility and receipt.ResultsOf approximately 600,000 annual cancer deaths in the US, 31.4% were from screenable cancer types, including colorectal, female breast, cervical, and smoking-associated lung cancers. Further accounting for the low receipt of lung cancer screening reduced the proportion to 17.4%; accounting for receipt of other screening reduced it to 12.8%. Thus, we estimated that current implementation of recommended screening may not address as much as 87.2% of cancer deaths-including 30.4% from individually uncommon cancer types unlikely ever to be covered by dedicated screening.ConclusionsThe large proportion of cancer deaths unaddressed by current screening represents a major opportunity for improved implementation of current approaches, as well as new multi-cancer screening technologies.
View details for DOI 10.1177/18758592241308754
View details for PubMedID 40109213